1.Treatment of Mycobacterium avium Complex Pulmonary Disease.
Yong Soo KWON ; Won Jung KOH ; Charles L DALEY
Tuberculosis and Respiratory Diseases 2019;82(1):15-26
The pathogen Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacterial pulmonary disease worldwide. The decision to initiate long-term antibiotic treatment is difficult for the physician due to inconsistent disease progression and adverse effects associated with the antibiotic treatment. The prognostic factors for the progression of MAC pulmonary disease are low body mass index, poor nutritional status, presence of cavitary lesion(s), extensive disease, and a positive acid-fast bacilli smear. A regimen consisting of macrolides (clarithromycin or azithromycin) with rifampin and ethambutol has been recommended; this regimen significantly improves the treatment of MAC pulmonary disease and should be maintained for at least 12 months after negative sputum culture conversion. However, the rates of default and disease recurrence after treatment completion are still high. Moreover, treatment failure or macrolide resistance can occur, although in some refractory cases, surgical lung resection can improve treatment outcomes. However, surgical resection should be carefully performed in a well-equipped center and be based on a rigorous risk-benefit analysis in a multidisciplinary setting. New therapies, including clofazimine, inhaled amikacin, and bedaquiline, have shown promising results for the treatment of MAC pulmonary disease, especially in patients with treatment failure or macrolide-resistant MAC pulmonary disease. However, further evidence of the efficacy and safety of these new treatment regimens is needed. Also, a new consensus is needed for treatment outcome definitions as widespread use of these definitions could increase the quality of evidence for the treatment of MAC pulmonary disease.
Amikacin
;
Body Mass Index
;
Clofazimine
;
Consensus
;
Disease Progression
;
Ethambutol
;
Humans
;
Lung
;
Lung Diseases
;
Macrolides
;
Mycobacterium avium Complex*
;
Mycobacterium avium*
;
Mycobacterium*
;
Nontuberculous Mycobacteria
;
Nutritional Status
;
Recurrence
;
Rifampin
;
Sputum
;
Treatment Failure
;
Treatment Outcome
2.Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives.
Yon Ju RYU ; Won Jung KOH ; Charles L DALEY
Tuberculosis and Respiratory Diseases 2016;79(2):74-84
Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both immunocompromised and immunocompetent patients. The incidence and prevalence of NTM lung disease are increasing worldwide and rapidly becoming a major public health problem. For the diagnosis of NTM lung disease, patients suspected to have NTM lung disease are required to meet all clinical and microbiologic criteria. The development of molecular methods allows the characterization of new species and NTM identification at a subspecies level. Even after the identification of NTM species from respiratory specimens, clinicians should consider the clinical significance of such findings. Besides the limited options, treatment is lengthy and varies by species, and therefore a challenge. Treatment may be complicated by potential toxicity with discouraging outcomes. The decision to start treatment for NTM lung disease is not easy and requires careful individualized analysis of risks and benefits. Clinicians should be alert to those unique aspects of NTM lung disease concerning diagnosis with advanced molecular methods and treatment with limited options. Current recommendations and recent advances for diagnosis and treatment of NTM lung disease are summarized in this article.
Diagnosis*
;
Humans
;
Incidence
;
Lung Diseases*
;
Lung*
;
Mycobacterium
;
Mycobacterium avium Complex
;
Mycobacterium kansasii
;
Nontuberculous Mycobacteria
;
Prevalence
;
Public Health
;
Risk Assessment